Propanc Biopharma, Inc. (PPCB): debt financing — Propanc Biopharma enters $112,350 convertible note at 22% interest with 1800 Diagonal Lending

Propanc Biopharma, Inc.

Issued $112,350 convertible promissory note to 1800 Diagonal Lending LLC at a 22% annual interest rate.
Conversion price is 75% of average lowest trading price over 10 days prior to conversion, with 4.99% beneficial ownership cap.
Maturity date April 30, 2026; company can prepay at 120% premium within 90 days, 125% from 91-180 days.
Proceeds from $107,000 purchase price (after $5,350 original issue discount) used for general working capital.
Events of default include failure to pay, failure to issue conversion shares, and loss of OTC listing.

item 1.01 item 2.03 item 3.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Propanc Biopharma, Inc. incurred convertible notes of $112,350 at 22% per annum maturing April 30, 2026.

Instrument: convertible notes
Principal: $112,350
Rate: 22% per annum
Maturity: April 30, 2026
Event: incurrence

Exact text from the filing

Effective July 25, 2025, Propanc Biopharma, Inc. (the “Company”) entered into and closed a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $112,350 (the “Note”)

View on SEC.gov

10 debt financings filed in the last 30 days. Browse all debt financings →

Propanc Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-021560

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.